Computational approaches in design of nucleic acid-based therapeutics.

Recent advances in computational and experimental methods have led to novel avenues for therapeutic development. Utilization of nucleic acids as therapeutic agents and/or targets has been recently gaining attention due to their potential as high-affinity, selective molecular building blocks for various therapies. Notably, development of computational algorithms for predicting accessible RNA binding sites, identifying therapeutic target sequences, modeling delivery into tissues, and designing binding aptamers have enhanced therapeutic potential for this new drug category. Here, we review trends in drug development within the pharmaceutical industry and ways by which nucleic acid-based drugs have arisen as effective therapeutic candidates. In particular, we focus on computational and experimental approaches to nucleic acid-based drug design, commenting on challenges and outlooks for future applications.

[1]  Jonathan Rasmussen,et al.  Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. , 2017, ACS nano.

[2]  Steven W. Sowa,et al.  Exploiting post-transcriptional regulation to probe RNA structures in vivo via fluorescence , 2014, Nucleic acids research.

[3]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[4]  K. Ulbrich,et al.  Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. , 2016, Chemical reviews.

[5]  Peter F. Stadler,et al.  ViennaRNA Package 2.0 , 2011, Algorithms for Molecular Biology.

[6]  J. Bujnicki,et al.  ModeRNA: a tool for comparative modeling of RNA 3D structure , 2011, Nucleic acids research.

[7]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[8]  D. Tieleman,et al.  The MARTINI force field: coarse grained model for biomolecular simulations. , 2007, The journal of physical chemistry. B.

[9]  K. Miyata.  Smart polymeric nanocarriers for small nucleic acid delivery. , 2016, Drug discoveries & therapeutics.

[10]  S. Hammond,et al.  Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy , 2017, Nucleic acid therapeutics.

[11]  K. Earm,et al.  Integrative approach in the era of failing drug discovery and development , 2014, Integrative medicine research.

[12]  Juewen Liu,et al.  Functional nucleic acid sensors. , 2009, Chemical reviews.

[13]  Aniket Magarkar,et al.  Rational design of liposomal drug delivery systems, a review: Combined experimental and computational studies of lipid membranes, liposomes and their PEGylation. , 2016, Biochimica et biophysica acta.

[14]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[15]  Tamar Schlick,et al.  Opportunities and Challenges in RNA Structural Modeling and Design. , 2017, Biophysical journal.

[16]  Lydia M. Contreras,et al.  Defective Ribonucleoproteins, Mistakes in RNA Processing, and Diseases. , 2017, Biochemistry.

[17]  Hong-ming Ding,et al.  Theoretical and computational investigations of nanoparticle-biomembrane interactions in cellular delivery. , 2015, Small.

[18]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[19]  John J. Cummings,et al.  Selective small-molecule inhibition of an RNA structural element , 2015, Nature.

[20]  Mengmeng Gong,et al.  CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein , 2017, Molecular Genetics and Genomics.

[21]  Feng-Xu Wu,et al.  ACFIS: a web server for fragment-based drug discovery , 2016, Nucleic Acids Res..

[22]  Razvan Nutiu,et al.  In vitro selection of structure-switching signaling aptamers. , 2005, Angewandte Chemie.

[23]  Magdalena A. Jonikas,et al.  Coarse-grained modeling of large RNA molecules with knowledge-based potentials and structural filters. , 2009, RNA.

[24]  D. Vanrompay,et al.  Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs , 2015, Pharmaceutical Research.

[25]  Seung Soo Oh,et al.  Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing , 2010, Proceedings of the National Academy of Sciences.

[26]  C. Stein,et al.  FDA-Approved Oligonucleotide Therapies in 2017. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  I. Hofacker,et al.  Predicting RNA 3D structure using a coarse-grain helix-centered model , 2015, RNA.

[28]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[29]  F. Dehne,et al.  Computational approaches toward the design of pools for the in vitro selection of complex aptamers. , 2010, RNA.

[30]  Justin K H Liu.  The history of monoclonal antibody development – Progress, remaining challenges and future innovations , 2014, Annals of medicine and surgery.

[31]  A. Cederbaum,et al.  The role of CYP2A5 in liver injury and fibrosis: chemical-specific difference , 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

[32]  T. Schirrmann,et al.  Phage display-derived human antibodies in clinical development and therapy , 2016, mAbs.

[33]  T. CrookeStanley.  Molecular Mechanisms of Antisense Oligonucleotides. , 2017 .

[34]  Janusz M Bujnicki,et al.  Computational modeling of RNA 3D structures and interactions. , 2016, Current opinion in structural biology.

[35]  H. Gerber,et al.  Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy. , 2016, ACS medicinal chemistry letters.

[36]  Silvio Bicciato,et al.  APTANI: a computational tool to select aptamers through sequence-structure motif analysis of HT-SELEX data , 2015, Bioinform..

[37]  Sergei A. Spirin,et al.  NPIDB: nucleic acid—protein interaction database , 2012, Nucleic Acids Res..

[38]  L. Dijkhuizen,et al.  Martini Coarse-Grained Force Field: Extension to DNA. , 2015, Journal of chemical theory and computation.

[39]  Peter C Anderson,et al.  Molecular simulations and Markov state modeling reveal the structural diversity and dynamics of a theophylline-binding RNA aptamer in its unbound state , 2017, PloS one.

[40]  Gary D Bader,et al.  BIND--The Biomolecular Interaction Network Database. , 2001, Nucleic acids research.

[41]  James H. Adair,et al.  A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma , 2017, Nucleic acid therapeutics.

[42]  Tamar Schlick,et al.  Challenges in RNA Structural Modeling and Design. , 2016, Journal of molecular biology.

[43]  Prabodhika Mallikaratchy,et al.  Ligand-Guided Selection of Target-Specific Aptamers: A Screening Technology for Identifying Specific Aptamers Against Cell-Surface Proteins. , 2016, Nucleic acid therapeutics.

[44]  A. Aartsma-Rus.  FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. , 2017, Nucleic acid therapeutics.

[45]  A. Datta-Mannan,et al.  Monoclonal Antibodies: Past, Present and Future. , 2019, Handbook of experimental pharmacology.

[46]  D. O'Hagan,et al.  Strategies for radiolabelling antibody, antibody fragments and affibodies with fluorine-18 as tracers for positron emission tomography (PET) , 2017 .

[47]  L. Motte,et al.  Vectorization of Nucleic Acids for Therapeutic Approach: Tutorial Review. , 2016, ACS chemical biology.

[48]  Peter F. Stadler,et al.  Thermodynamics of RNA-RNA Binding , 2006, German Conference on Bioinformatics.

[49]  Jianhui Gong,et al.  Correction of a pathogenic gene mutation in human embryos , 2017, Nature.

[50]  A. Krieg,et al.  FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga , 2017, Nucleic acid therapeutics.

[51]  D. Frenkel,et al.  Intracellular release of endocytosed nanoparticles upon a change of ligand-receptor interaction. , 2012, ACS nano.

[52]  R. Batey,et al.  Determining structures of RNA aptamers and riboswitches by X-ray crystallography. , 2009, Methods in molecular biology.

[53]  F. Major,et al.  The MC-Fold and MC-Sym pipeline infers RNA structure from sequence data , 2008, Nature.

[54]  Rolf Backofen,et al.  IntaRNA 2.0: enhanced and customizable prediction of RNA–RNA interactions , 2017, Nucleic Acids Res..

[55]  Srinivasan Ramachandran,et al.  In silico selection of an aptamer to estrogen receptor alpha using computational docking employing estrogen response elements as aptamer-alike molecules , 2016, Scientific Reports.

[56]  S. Bishop,et al.  Critical considerations for developing nucleic acid macromolecule based drug products. , 2016, Drug discovery today.

[57]  A. Rescifina,et al.  Recent advances in small organic molecules as DNA intercalating agents: synthesis, activity, and modeling. , 2014, European journal of medicinal chemistry.

[58]  Yingfu Li,et al.  Structure-switching signaling aptamers. , 2003, Journal of the American Chemical Society.

[59]  Michael Zuker,et al.  Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..

[60]  Yong Wang,et al.  Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9 , 2017, Science.

[61]  Li-Zhen Sun,et al.  Theory and Modeling of RNA Structure and Interactions with Metal Ions and Small Molecules. , 2017, Annual review of biophysics.

[62]  Kristofer G. Reyes,et al.  Optimization of a novel biophysical model using large scale in vivo antisense hybridization data displays improved prediction capabilities of structurally accessible RNA regions , 2017, Nucleic acids research.

[63]  E. Mercuri,et al.  Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues , 2017, Nucleic acid therapeutics.

[64]  Xing Chen,et al.  Long non-coding RNAs and complex diseases: from experimental results to computational models , 2016, Briefings Bioinform..

[65]  Alexander D. MacKerell,et al.  Computational ligand-based rational design: Role of conformational sampling and force fields in model development. , 2011, MedChemComm.

[66]  Jangam Vikram Kumar,et al.  Computational Selection of RNA Aptamer against Angiopoietin-2 and Experimental Evaluation , 2015, BioMed research international.